ALDA Receives Notice of Allowance for Canadian Patent
06 Abril 2011 - 1:15PM
Marketwired
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF)
("ALDA") has been notified that the Canadian Intellectual Property
Office ("CIPO") has accepted ALDA's patent application that
describes the composition, production methods and certain
therapeutic uses for ALDA's T36® formulation.
In addition, the Company has two patents issued in the both the
US and Australia, one issued in China and one pending in both China
and the EU. An additional patent application, seeking protection
for the T36® formula in combination with anesthetics, analgesics
and anti-inflammatories for the treatment of a wide range of
topical infections has been filed in the US and the EU.
Dr. Terrance Owen, President & CEO, states, "Notification
that the patent will now be issued in Canada provides further
evidence that our intellectual property is very robust. We are
gratified to see rapid allowance of the patent applications in a
number of jurisdictions. Clearly, ALDA's T36® formulation is unique
and is a significant asset to the company."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control
therapeutics derived from its patented T36® technology. The company
trades on the TSX Venture Exchange under the symbol APH and on the
OTCQB under the symbol APCSF. The Company was the Official Supplier
to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010
Paralympic Winter Games and is the Official Supplier to the
Canadian Olympic Committee, the 2010 Canadian Olympic Team and the
2012 Canadian Olympic Team for antiseptic hand sanitizer,
disinfectant and disinfectant cleaning products. The Company was
also selected as one of the TSX Venture 50 companies in the
Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements:
Information in this press release that involves ALDA's
expectations, plans, intentions or strategies regarding the future
are forward-looking statements that are not facts and involve a
number of risks and uncertainties. ALDA generally uses words such
as "outlook", "will", "could", "would", "might", "remains", "to
be", "plans", "believes", "may", "expects", "intends",
"anticipates", "estimate", "future", "plan", "positioned",
"potential", "project", "remain", "scheduled", "set to", "subject
to", "upcoming", and similar expressions to help identify
forward-looking statements. The forward-looking statements in this
release are based upon information available to ALDA as of the date
of this release, and ALDA assumes no obligation to update any such
forward-looking statements. Forward-looking statements believed to
be true when made may ultimately prove to be incorrect. These
statements are not guarantees of the future performance of ALDA and
are subject to risks, uncertainties and other factors, some of
which are beyond its control and may cause actual results to differ
materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor
Relations 604-377-5781 or 604-521-8300 Ext 203 604-521-8322 (FAX)
scott_young@aldacorp.com www.aldacorp.com
Aphria Inc. (TSXV:APH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aphria Inc. (TSXV:APH)
Gráfica de Acción Histórica
De May 2023 a May 2024